Li Juan, Shen Xingping
1Department of Emergency, Zhongshan Hospital Xiamen University, Xiamen, 361004 Fujian China.
2Department of Endocrinology, Zhongshan Hospital Xiamen University, Xiamen, 361004 Fujian China.
Diabetol Metab Syndr. 2019 May 3;11:35. doi: 10.1186/s13098-019-0432-z. eCollection 2019.
To evaluate the effect of insulin sensitizer on inflammatory cytokines and oxidative stress in patients with newly diagnosed type 2 diabetes mellitus (T2DM).
After intensive insulin therapy, patients with newly diagnosed T2DM were continuously treated with either insulin sensitizer or insulin for 48 weeks, and then their inflammatory cytokine and oxidative stress levels were measured.
Tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, hypersensitive C reactive protein (hs-CRP), malondialdehyde (MDA), and 8-iso-prostaglandin F2α (8-iso-PGF) levels of the rosiglitazone (RSG) group and the rosiglitazone combined with metformin (RSG + metformin) group were significantly reduced after the treatments ( < 0.05). Hs-CRP, MDA, and 8-iso-PGF levels of the metformin group were significantly reduced after the treatments ( < 0.05). Superoxide dismutase (SOD) and total antioxidant capacity (TAC) were significantly increased after the treatments in all three groups ( < 0.05 and < 0.01).
Early application of insulin sensitizers improved inflammation and oxidative stress in patients with newly diagnosed T2DM.
评估胰岛素增敏剂对新诊断2型糖尿病（T2DM）患者炎症细胞因子和氧化应激的影响。
新诊断的T2DM患者在强化胰岛素治疗后，继续接受胰岛素增敏剂或胰岛素治疗48周，然后测量其炎症细胞因子和氧化应激水平。
治疗后，罗格列酮（RSG）组和罗格列酮联合二甲双胍（RSG+二甲双胍）组的肿瘤坏死因子α（TNF-α）、白细胞介素（IL）-6、超敏C反应蛋白（hs-CRP）、丙二醛（MDA）和8-异前列腺素F2α（8-iso-PGF）水平显著降低（<0.05）。治疗后，二甲双胍组的hs-CRP、MDA和8-iso-PGF水平显著降低（<0.05）。三组治疗后超氧化物歧化酶（SOD）和总抗氧化能力（TAC）均显著升高（<0.05和<0.01）。
早期应用胰岛素增敏剂可改善新诊断T2DM患者的炎症和氧化应激。
